Next Article in Journal
Comprehensive Phenolic Profiling of Cyclopia genistoides (L.) Vent. by LC-DAD-MS and -MS/MS Reveals Novel Xanthone and Benzophenone Constituents
Previous Article in Journal
Synthesis of Novel Bisindolylmethane Schiff bases and Their Antibacterial Activity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 19
Issue 8
10.3390/molecules190811741
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

New Eco-Friendly 1-Alkyl-3-(4-phenoxybutyl) Imidazolium-Based Ionic Liquids Derivatives: A Green Ultrasound-Assisted Synthesis, Characterization, Antibacterial Activity and POM Analyses

by
Mouslim Messali
1,*,
Mohamed R. Aouad
1,2,
Wael S. El-Sayed
3,4,
Adeeb Al-Sheikh Ali
1,
Taibi Ben Hadda
5 and
Belkheir Hammouti
6
1
Department of Chemistry, Taibah University, Al-Madina Al-Mounawara 30002, Saudi Arabia
2
Laboratoire de Chimie & Electrochimie des Complexes Métalliques (LCECM) USTO-MB, University of Sciences and Technology Mohamed Boudiaf, BP 1505 Oran, El M'nouar, Algeria
3
Microbiology department, Faculty of Science, Ain Shams University, Cairo 11566, Egypt
4
Biology Department, Taibah University, Al-Madina Al-Mounawara 30002, Saudi Arabia
5
Laboratoire de Chimie des Matériaux, Faculté des Sciences, Université Mohammed Premier, Oujda-60000, Morocco
6
LCAE-URAC18, Faculté des Sciences, Université Mohammed Premier, B.P. 717, Oujda-60000, Morocco
*
Author to whom correspondence should be addressed.
Molecules 2014, 19(8), 11741-11759; https://doi.org/10.3390/molecules190811741
Submission received: 4 June 2014 / Revised: 2 July 2014 / Accepted: 14 July 2014 / Published: 7 August 2014
(This article belongs to the Section Organic Chemistry)
Browse Figures
Versions Notes

Abstract

:
In view of the emerging importance of the ILs as “green” materials with wide applications and our general interests in green processes, a series of a twenty five new 1-alkyl-3-(4-phenoxybutyl) imidazolium-based ionic liquids (ILs) derivatives is synthesized using a facile and green ultrasound-assisted procedure. Their structures were characterized by FT-IR, 1H-NMR, 13C-NMR, 11B, 19F, 31P, and mass spectrometry. Antimicrobial screens of some selected ILs were conducted against a panel of Gram-positive and Gram-negative bacteria. The antimicrobial activity of each compound was measured by determination of the minimal inhibitory concentration (MIC) yielding very interesting and promising results. Their antibacterial activities are reported, and, on the basis of the experimental and virtual POM screening data available, attempt is also made to elucidate the structure activity relationship.

Graphical Abstract

1. Introduction

Over the past two decades, Ionic liquids (ILs) have attracted considerable attention as friendly environmental substitutes for volatile organic solvents due to the several unique properties such as negligible vapor pressure, high thermal stability, easy recyclability, no flammability, and high ionic conductivity [1,2,3,4]. Generally, ILs are a group of low-melting-point salts containing organic cation, such as imidazolium, pyrrolidinium, or pyridazinium, paired with various anions, such as bromide or tetrafluoroborate [5].
Due to these unique properties, ILs have been widely synthesized and investigated as media for electrodeposition of metals [6,7,8], as a tool for lignocellulosic biomass fractionation [9], catalysis and biocatalysis [10,11,12,13,14,15,16], corrosion inhibition [17,18,19,20], food chemical science [21], and the nuclear industry [22].
Thus far, many chemists promoted to explore new procedures for the clean and efficient synthesis of ILs since the conventional syntheses of them are not benign [23]. Several modifications have been attempted including microwave irradiation, sonochemical reactions or solvent-free reactions. The use of these green technologies leads to many advantages, such as large reductions in reaction times, enhancements in conversions, sometimes in selectivity [24,25,26,27].
On the other hand, numerous studies have demonstrated the antimicrobial activity of various classes of ionic liquids against both environmental and clinically important microorganisms [28,29,30,31,32,33].
According to the above mentioned, and our ongoing research, interest in ionic liquids synthesis [34,35,36], we continued to combine the use of green technologies in the synthesis of new class of antimicrobial agents.
Some selected ILs were investigated for their anti-microbial activity against different pathogenic strains.

2. Results and Discussion

2.1. Chemistry

In continuation of our previous work dealing with the development of novel room temperature functionalized ionic liquids [37], herein, we report the synthesis of a variety of new imidazolium-based ionic liquids under both conventional and ultrasound irradiation methods (Scheme 1 and Scheme 2).
Molecules 19 11741 g001 550
Scheme 1. Synthesis of a variety of new imidazolium-based ionic liquids under both conventional and ultrasound irradiation methods.
Scheme 1. Synthesis of a variety of new imidazolium-based ionic liquids under both conventional and ultrasound irradiation methods.
Molecules 19 11741 g001
(i) N-alkylation of imidazole: RBr, (KOH/K2CO3), Acetonitrile, 80 °C, 16 h. R = Et, Pr, Bu, Pent, Hex, Benzyl. (ii) N-alkylation of N-alkylimidazole: conventional preparation (CP) and ultrasonic irradiation conditions (US). (CP): PhO(CH2)4Br, toluene, 80 °C, 18 h; (US): toluene, 80 °C, 5 h.
Molecules 19 11741 g002 550
Scheme 2. Anion metathesis using conventional preparation (CP) and ultrasonic irradiation conditions (US). (CP): MY, dichloromethane, 70 °C, 3 h; (US): dichloromethane, 70 °C, 45 min. M = Na, K.
Scheme 2. Anion metathesis using conventional preparation (CP) and ultrasonic irradiation conditions (US). (CP): MY, dichloromethane, 70 °C, 3 h; (US): dichloromethane, 70 °C, 45 min. M = Na, K.
Molecules 19 11741 g002
Initially, various 1-alkyl-1H-imidazole 1–6 were easily prepared by treatment of imidazole with alkyl bromide with K2CO3/KOH in Acetonitrile. The nucleophilic alkylation of N-alkylelimidazoles 1–6 under standard conditions (toluene, 80 °C, 18 h), with different alkyl halides (1.1 eq) afforded the corresponding imidazolium halides in 78%–85% yield as oils after solvent removal by evaporation (Table 1).
Table
Table 1. Reaction conditions and yields for the quaternization of N-alkylimidazole (7–12) using conventional preparation (CP) and ultrasound irradiation conditions (US).
Table 1. Reaction conditions and yields for the quaternization of N-alkylimidazole (7–12) using conventional preparation (CP) and ultrasound irradiation conditions (US).
CompoundRYield (%) of the Quaternization Step
CP1 aUS b
7Et7985
8Pr8087
9Bu7889
10Pent7988
11Hex8087
12CH2Ph7986
a Time (18 h), Temperature (80 °C) in toluene; b Time (5 h), Temperature (80 °C) in toluene.
Previous work reports that the hydrophobicity of an ionic liquid increases with the length of the alkyl chain on the imidazolium ring, and this increase tends to raise viscosity [38,39]. This why six anions were used in the metathesis step in order to obtain low melting point and less viscous ILs.
The next step in the synthesis involved an anion exchange halides by using a slight excess of the anions sodium tetrafluoroborate, potassium hexafluorophosphate, trifluoroacetic acid sodium, sodium dicyanamide, sodium thiocyanate, or sodium nitrate anions (Scheme 2).
The resulting pure products from these reactions were subsequently obtained by filtration of the metal halide salts, followed by filtrate evaporation and washing of the residue with dichloromethane followed by further filtration to remove any remaining metal salts. Finally, evaporation of the filtrate afforded the desired ionic liquids 13–36 in good yields (Table 2).
As already reported by our team, an anion exchange metathesis is easily performed by ultrasonic activation [34]. In a similar way, the preparation of ILs 13–36 was carried in a closed vessel and exposed to irradiation for 45 min at 70 °C using a sonication bath. The data presented in Table 2 indicated that very good yields were obtained in very short reaction times. As observed, the anion nature of the exchange agents did not affect product yields.
Table
Table 2. Reaction conditions and yields for the anion metathesis reaction using conventional preparation (CP) and ultrasound irradiation conditions (US).
Table 2. Reaction conditions and yields for the anion metathesis reaction using conventional preparation (CP) and ultrasound irradiation conditions (US).
CompoundRMYYield (%) for the Anion Metathesis
CP2 a(US) b
13PrNaBF49596
14KPF69597
15NaOOCCF39298
16NaN(CN)29497
17NaNCS9297
18NaNO39495
19BuNaBF49498
20KPF69397
21NaOOCCF39397
22NaN(CN)29296
23NaNCS9395
24NaNO39296
25PentNaBF49598
26KPF69396
27NaOOCCF39597
28NaN(CN)29497
29NaNCS9495
30NaNO39498
31HexNaBF49497
32KPF69396
33NaOOCCF39597
34NaN(CN)29296
35NaNCS9395
36NaNO39497
a Time (3 h), Temperature (70 °C) in acetonitrile; b Time (45 min), Temperature (70 °C) in acetonitrile.
The structures of all the newly synthesized ionic liquids were confirmed by 1H-NMR, 13C-NMR, 11B-NMR, 19F-NMR, 31P-NMR, FT-IR, and LCMS analysis. All spectroscopic data are detailed in the experimental part.

2.2. Antimicrobial Activity

The short generation times of bacteria compared with other living organisms give a good starting point to examine the toxicity of ILs [40]. This has indirectly led to the realization that some ILs exhibit anti-microbialactivity.
One of the objectives of the present study is therefore to investigate the anti-microbial activities of some synthesized ILs. For this, several types of human pathogens were selected to assess the potential toxicities of these ILs and theireffectiveness as anti-microbial agents.
In this aim, the water soluble ILs 7–12 were tested in vitro for their antibacterial activity against Gram-positive bacteria including; Staphylococcus aureus, Streptococcus pneumonia, Bacillus subtilis and Bacillus cereus, as well as Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. These clinical isolates were selected based on their pathogenic properties. The antibacterial activity was measured by determination of MIC values in a range from 0 to 256 µg/mL and compared with those of some potent antibacterial compounds like mezlocillin, amikacin, tetracycline and nitrofurantion. MIC values are summarized (Table 3).
From the MIC values obtained, all compounds exhibited antibacterial activity with varying potential as well as spectrum. In general, all tested ILs (7–12) possessed congruent antibacterial activities against the growth of E. coli, K. pneumoniae, S. aureus and S. pneumoniae as compared with the standards mezlocillin, amikacin, tetracycline, and nitrofurantion while showed low activity (>128 µg/mL) against P. aeruginosa and A. baumannii.
Table
Table 3. Antimicrobial activity of Ionic liquids 7–12 against eight bacterial strains.
Table 3. Antimicrobial activity of Ionic liquids 7–12 against eight bacterial strains.
CompoundsMIC (µg/mL)
E. coliK. pneumoniaeP. aeruginosaA. baumanniiS. aureusS. pneumoniaeB. subtilisB. cereus
76464>256>2566464128>256
83216>256>2566464128>256
91616>256>2563216128>256
101681282561686464
11168>256128881632
121632>256>256643264>256
Mezlocillin128128128128------3232
Amikacin323232323232------
Tetracycline1616---16---844
Nitrofurantion128128------128128------
In particular, IL 11 exhibited the highest antibacterial activities in the series against most of the tested bacteria with MIC values (<32 µg/mL). Having MIC value of 8 for IL 11 against K. pneumoniae, S. aureus, and S. pneumonia makes it a good candidate as a potent antibacterial agent. Such relatively high antibacterial activity of IL 11 can be attributed to the presence of the hexyl chain which is absent in the IL 7 having lowest toxicity. This trend was also found in case of IL 9 and 10. Therefore, it can be concluded that the biological activity of ILs 7–11 depends on the length of the alkyl chain and increased with increasing the hydrophobicity for the tested ILs.
Beside antibacterial activity, all tested ILs (7–12) showed broader spectrum revealed by detected antibacterial activity against Gram-positive and Gram-negative bacteria, particularly S. aureus, S. pneumonia and E. coil, K. pneumonia, respectively.

2.3. POM Analyses of Compounds 7–12

For a molecule to be a potential drug, besides having a good biological activity, it must have good pharmacokinetic properties in biological systems. To access the pharmacokinetic profile of the synthesized molecules, we used well validated in silico tools: Osiris, Petra and Molinspiration. These tools have been validated with almost 7000 drug molecules available on the market.
The analysis of theoretical toxicity risks for the similar ILs using the Osiris program showed that similar ILs were less toxic than standard clinical drugsand can be used as therapeutic agents.
From the data evaluated in Table 4 indicates that, all structures are supposed to be non-mutagenic when run through the mutagenicity assessment system and, as far as irritating and reproductive effects are concerned, all the compounds are at low risk comparable with standard drugs used. The hydrophilicity character of each compound has been expressed in term of the log p value which correspond to the logarithm of its partition coefficient between n-octanol and water. It has been established that the absorption or permeation is greatly affected by the hydrophilicity (value of Log p). Accordingly, when Log p is higher than 5, the absorption or permeation decrease.
On this basis, all the majority of compounds 7–12 is having log P values under the acceptable criteria should be active but they are not active because there is another crucial parameter which should be taken in consideration. It concerns the geometrical conformation of pharmacophore. The absorption, distribution characteristics and bioactivity was proved to be dependent to the geometrical parameter and the aqueous solubility of a compound. Consequently, the bad absorption could presumably due to the low solubility of the tested ILs. Further, the Table 4 shows drug-likeness of compounds 7–12 which is not in the comparable zone with that of standard drugs used.
We have calculated overall drug-score (DS) for the compounds 7–12 and compared with that of standard drugs (AMP, GENTA, and AMPHO) used as shown in Table 4 and Table 5. The DS combines drug-likeness, log p, log S, molecular weight, and toxicity risks, in one handy value that may be used to judge the compound’s overall potential to qualify for a drug. The reported compounds 7–12 showed low to moderate DS as compared with standard drugs used.
Table
Table 4. Osiris calculations of toxicity risks and drug-score of compounds 7–12. Molecules 19 11741 i001
Table 4. Osiris calculations of toxicity risks and drug-score of compounds 7–12. Molecules 19 11741 i001
Compd.RToxicity Risks [a]Drug-Score [b]
MUTTUMOIRRIREPCLPSDLDS
7Ethyl Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i0022.38−2.67−0.660.60
8Propyl Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i0022.84−2.94−0.900.56
9Butyl Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i0023.31−3.21−3.160.43
10Pentyl Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i0023.77−3.48−5.850.39
11Hexyl Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i0024.23−3.76−10.230.36
12Benzyl Molecules 19 11741 i003 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i0023.31−3.69−0.910.41
Mezlocillin--- Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002−0.03−2.5315.140.66
Amikacin--- Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i004 Molecules 19 11741 i002−8.00−0.231.730.35
Tetracycline--- Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002−1.02−1.835.430.81
Nitrofurantion--- Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002 Molecules 19 11741 i002−0.07−2.500.670.78
Molecules 19 11741 i002: not toxic; Molecules 19 11741 i003: slightly toxic; Molecules 19 11741 i004: highly toxic. [a] MUT: mutagenic; TUMO: tumorigenic; IRRI: irritant; REP: reproductive effective. [b] CLP: cLogP, S: Solubility, DL: Druglikness, DS: Drug-Score.

2.4. Molinspiration Calculations

cLog P (octanol/water partition coefficient) is calculated by the methodology developed by Molinspiration as a sum of fragment based contributions and correction factors (Table 4). The method is very useful and can be applied to all organic and some organometallic molecules. Molecular Polar Surface Area values (TPSA) were also measured using the above mentioned methodology. O– and N– centred polar fragments are considered. PSA has been shown to be a useful parameter for determination of drug absorption and especially intestinal absorption, bioavailability, and blood–brain barrier penetration. Prediction results of compounds 7–12 molecular properties (TPSA, GPCR ligand, and ICM) are valued (Table 5).
Table
Table 5. Molinspiration calculations of compounds 7–12.
Table 5. Molinspiration calculations of compounds 7–12.
Compd.MW(g/mol)Physico-Chemical Properties [a]Drug Likeness [b]
TPSAO/NHVIOLVOLGPCICMKINRLPIEN
732512.4700271−0.06−0.10−0.18−0.06−0.220.01
833912.47002870.04−0.06−0.130.03−0.100.03
935312.47003040.07−0.06−0.100.08−0.050.05
1036712.47003210.10−0.05−0.070.120.010.07
1138112.47003380.12−0.05−0.050.130.030.06
1238712.47003250.09−0.06−0.010.080.040.04
Mezlocillin53917332434−0.04−0.43−0.60−0.580.660.10
Amikacin5853321735100.32−0.090.16−0.100.780.45
Tetracycline44418271377−0.15−0.24−0.53−0.09−0.040.52
Nitrofurantion23812110181−1.36−0.90−1.21−2.16−1.45−0.79
[a] TPSA: Total polar surface area; O/NH: O---HN interaction; VIOL: number of violation; VOL: volume. [b] GPC: GPCR ligand; ICM: Ion channel modulator; KI: Kinase inhibitor; NRL: Nuclear receptor ligand; PI: Protease inhibitor; EI: Enzyme inhibitor.
The bioactivity properties were greatly affected by the electronic and steric factors. The obtained POM results confirm that most of these ILs could be used as potential antimicrobial activity after major modifications. Based on their great hydrosolubility properties, these compounds may be useful as solubilising substituents with potential anti-tumoralactivity. These results prompt several pertinent observations: (i) This type of ILs can furnish an interesting model for studying the interaction of target-antibiotics complexes with cancer phosphates because the possible charge (P=Oδ---Nδ+) modification of pi-charge pharmacophore group; (ii) The future flexiblelipophyl-hydrosoluble drugs containing Il moiety will enable us to prepare molecules for multi-therapeutic materials with high combined antibacterial/antiviral/antifungal/antitumoral activity.

3. Materials and Methods

3.1. Experimental

All new compounds were synthesized and characterized by 1H-NMR, 13C-NMR, IR, and LCMS. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were measured in CDCl3 at room temperature. Chemical shifts (δ) were reported in ppm to a scale calibrated for tetramethylsilane (TMS), which is used as an internal standard. The LCMS spectra were measured with a Micromass, LCT mass spectrometer. IR spectra were recorded in NaCl or KBr disc on a Schimadzu 8201 PC, FTIR spectrophotometer (υmax in cm−1). The ultrasound-assisted reactions were performed using a high intensity ultrasonic processor SUB Aqua 5 Plus-Grant with temperature controller (750 W), microprocessor controlled-2004, the ultrasonic frequency of the cleaning bath used equal 25 KHz.

3.2. Synthesis

General procedures for the synthesis of imidazolium halides (7–12) using conventional method. To the solution of N-alkylimidazole (1 eq) in toluene, was added alkyl bromide (1.1 eq) at room temperature, followed by stirring at 80 °C for 18 h. The completion of the reaction was marked by the separation of oil from the initially obtained clear and homogenous mixture of N-alkylimidazole and alkyl halide in toluene. The product was isolated by extraction to remove the unreacted starting materials and solvent. Subsequently, the imidazolium salt was washed with ethyl acetate. In each case, the IL/salt was finally dried at a reduced pressure to get rid of all the volatile organic compounds.
General procedure for the synthesis of imidazolium halides (7–12) using under Ultrasonic irradiation. Alkylimidazole (1 eq) and the appropriate alkyl bromide (1 eq) were placed in a closed vessel and exposed to irradiation for 5 h at 80 °C using a sonication bath. The product was then collected as described in the conventional procedure outlined earlier.
General procedure for the methathesis reaction of (8–11) leading to compounds (13–36) using conventional method. The quaternary salt (1 eq) was dissolved in dichloromethane to obtain a clear solution. To this solution of quaternary halide was added solution of sodium tetrafluoroborate, potassium hexafluorophosphate, trifluoroacetic acid sodium, sodium dicyanamide, sodium thiocyanate, or sodium nitrate (1.2 eq), followed by stirring at 70 °C for 3 h. The cooled reaction mixture was filtered through Celite to remove solid metal halide. The evaporation of dichloromethane leaded quantitatively to the desired ionic liquids.
General procedure for the ultrasound-assisted methathesis reaction of (8–11) leading to compounds (13–36). Imidazolium-halides salts (1 eq) and NaBF4, KPF6, CF3COONa, NaN(CN)2, NaNCS or NaNO3 (1 eq) were placed in a closed vessel and exposed to irradiation for 45 min at 70 °C using a sonication bath. The product was then collected as described in the conventional procedure outlined earlier.

3.3. Characterization

1-Ethyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium bromide (7). 1H-NMR (CDCl3, 400 MHz): δ = 1.40 (t, J = 7.2 Hz, 3H), 1.69 (quint, J = 7.6 Hz, 2H), 1.96 (quint, J = 7.6 Hz, 2H), 3.96 (t, J = 7.6 Hz, 2H), 4.23 (q, J = 7.2 Hz, 2H), 4.30 (t, J = 7.6 Hz, 2H), 6.87–6.91 (m, 3H, Ar-H), 7.22–7.27 (m, 2H, Ar-H), 7.93–7.99 (m, 2H), 9.55 (s, 1H); 13C-NMR (CDCl3, 100 MHz): δ = 15.0 (CH3), 25.3 (CH2), 26.3 (CH2), 44.1 (CH2), 48.4 (CH2), 66.6 (CH2), 114.3 (CH), 120.4 (CH), 122.1 (CH), 122.3 (CH), 129.4 (CH), 135.8 (CH), 158.3 (C); IR (NaCl) υmax 3132 (C-H Ar), 1599–1471 (C=C), 1165(C-N), 1082 (C-O) cm−1; LCMS (M+)-Br− 245.2 found for C15H21N2O+.
1-Propyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium bromide (8). 1H-NMR (CDCl3, 400 MHz): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.76 (quint, J = 7.6 Hz, 2H), 1.88 (sextet, J = 7.6 Hz, 2H), 2.07 (quint, J = 7.6 Hz, 2H), 3.93 (t, J = 7.6 Hz, 2H), 4.21 (t, J = 7.2 Hz, 2H), 4.40 (t, J = 7.6 Hz, 2H), 6.77–6.86 (m, 3H, Ar-H), 7.15–7.19 (m, 2H, Ar-H), 7.50–7.58 (m, 2H, Ar-H), 10.22 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 10.7 (CH3), 23.6 (CH2), 25.8 (CH2), 27.3 (CH2), 49.6 (CH2), 51.3 (CH2), 66.7 (CH2), 114.4 (CH), 120.8 (CH), 122.3 (CH), 122.4 (CH), 129.5 (CH), 136.6 (CH), 158.5 (C); IR (NaCl) υmax 3131 (C-H Ar), 1599–1470 (C=C), 1164(C-N), 1083 (C-O) cm−1; LCMS (M+)-Br− 259.2 found for C16H23N2O+.
1-Butyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium bromide (9). 1H-NMR (CDCl3, 400 MHz): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.31 (sextet, J = 7.6 Hz, 2H), 1.78–1.82 (m, J = 7.6 Hz, 4H), 2.10 (quint, J = 7.6 Hz, 2H), 3.94 (t, J = 7.6 Hz, 2H), 4.25 (t, J = 7.2 Hz, 2H), 4.41 (t, J = 7.6 Hz, 2H), 6.79–6.86 (m, 3H, Ar-H), 7.17–7.21 (m, 2H, Ar-H), 7.47–7.58 (m, 2H, Ar-H), 10.22 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.4 (CH3), 19.4 (CH2), 25.8 (CH2), 27.3 (CH2), 32.1 (CH2), 48.7 (CH2), 49.6 (CH2), 66.8 (CH2), 114.4 (CH), 120.8 (CH), 122.2 (CH), 122.4 (CH), 129.5 (CH), 136.6 (CH), 158.5 (C); IR (NaCl) υmax 3133 (C-H Ar), 1600–1471 (C=C), 1166(C-N), 1082 (C-O) cm−1; LCMS (M+)-Br− 273.3 found for C17H25N2O+.
1-Pentyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium bromide (10). 1H-NMR (CDCl3, 400 MHz): δ = 0.67 (t, J = 7.2 Hz, 3H), 1.04–1.15 (m, 4H), 1.62–1.72 (m, 4H), 1.97 (quint, J = 7.6 Hz, 2H), 3.79 (t, J = 7.6 Hz, 2H), 4.11 (t, J = 7.2 Hz, 2H), 4.28 (t, J = 7.6 Hz, 2H), 6.79–6.86 (m, 3H, Ar-H), 7.65–7.71 (m, 2H, Ar-H), 7.02–7.06 (m, 2H, Ar-H), 10.13 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.7 (CH3), 21.8 (CH2), 25.7 (CH2), 27.2 (CH2), 28.0 (CH2), 29.7 (CH2), 49.4 (CH2), 49.8 (CH2), 66.6 (CH2), 114.2 (CH), 120.6 (CH), 122.2 (CH), 122.5 (CH), 129.3 (CH), 136.3 (CH), 158.4 (C); IR (NaCl) υmax 3132 (C-H Ar), 1600–1471 (C=C), 1164 (C-N), 1081 (C-O) cm−1; LCMS (M+)-Br− 287.3 found for C18H27N2O+.
1-Hexyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium bromide (11). 1H-NMR (CDCl3, 400 MHz): δ = 0.94 (t, J = 7.2 Hz, 3H), 1.14 (quint, J = 7.6 Hz, 2H), 1.39–1.41 (m, 4H), 1.69 (quint, J = 7.6 Hz, 2H), 1.77 (quint, J = 7.6 Hz, 2H), 1.96 (quint, J = 7.6 Hz, 2H), 3.96 (t, J = 7.6 Hz, 2H), 4.27 (quint, J = 7.2 Hz, 2H), 4.46 (t, J = 7.6 Hz, 2H), 6.87–6.91 (m, 3H, Ar-H), 7.22–7.27 (m, 2H, Ar-H), 7.93–7.99 (m, 2H, Ar-H), 9.55 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.9 (CH3), 22.6 (CH2), 24.8 (CH2), 27.2 (CH2), 27.3 (CH2), 32.6 (CH2), 33.9 (CH2), 44.1 (CH2), 48.3 (CH2), 66.6 (CH2), 114.3 (CH), 120.4 (CH), 122.1 (CH), 122.3 (CH), 129.4 (CH), 135.8 (CH), 158.3 (C); IR (NaCl) υmax 3132 (C-H Ar), 1598–1472 (C=C), 1165 (C-N), 1081 (C-O) cm−1; LCMS (M+)-Br− 301.3 found for C19H29N2O+.
1-Benzyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium bromide (12). White crystals, Mp 153–155 °C,1H-NMR (CDCl3, 400 MHz): δ = 1.77 (quint, J = 8, 2H), 2.07 (quint, J = 8 Hz, 2H), 3.91 (t, J = 8 Hz, 2H), 4.35 (t, J = 8 Hz, 2H), 5.52 (s, 2H), 6.77–6.88 (m, 3H), 7.17–7.55 (m, 9H), 10.45 (s, 1H); 13C-NMR (CDCl3, 100 MHz): δ = 25.7 (CH2), 26.9 (CH2), 49.7 (CH2), 53.2 (CH2), 66.7 (CH2), 114.4 (CH), 120.8 (CH), 122.2 (CH), 122.6 (CH), 128.9 (CH), 129.4 (CH), 129.5 (CH), 133.0 (C), 135.5 (CH), 158.6 (C); IR (KBr) υmax 3130 (C-H Ar), 1599–1471 (C=C), 1164 (C-N), 1081 (C-O) cm−1; LCMS (M+)-Br− 307.3.3 found for C20H23N2O+.
1-Propyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium tetrafluoroborate (13). 1H-NMR (CDCl3, 400 MHz): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.76 (quint, J = 7.6 Hz, 2H), 1.88 (sextet, J = 7.6 Hz, 2H), 2.07 (quint, J = 7.6 Hz, 2H), 3.93 (t, J = 7.6 Hz, 2H), 4.21 (t, J = 7.2 Hz, 2H), 4.40 (t, J = 7.6 Hz, 2H), 6.77–6.86 (m, 3H, Ar-H), 7.15–7.19 (m, 2H, Ar-H), 7.50–7.58 (m, 2H, Ar-H), 10.22 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 8.7 (CH3), 21.6 (CH2), 24.0 (CH2), 25.3 (CH2), 47.9 (CH2), 49.6 (CH2), 65.0 (CH2), 112.6 (CH), 119.0 (CH), 120.7 (CH), 122.2 (CH), 127.7 (CH), 133.7 (CH), 158.5 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −150.65; 11B-NMR (CDCl3, 128 MHz): δ = −0.96; IR (NaCl) υmax 3133 (C-H Ar), 1598–1472 (C=C), 1166 (C-N), 1084 (C-O) cm−1; LCMS (M+)-BF4− 259.2 found for C16H23N2O+.
1-Propyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium hexafluorophospate (14). 1H-NMR (CDCl3, 400 MHz): δ = 0.94 (t, J = 7.2 Hz, 3H), 1.80 (quint, J = 7.6 Hz, 2H), 1.87 (sextet, J = 7.6 Hz, 2H), 2.06 (quint, J = 7.6 Hz, 2H), 3.98 (t, J = 7.6 Hz, 2H), 4.10 (t, J = 7.2 Hz, 2H), 4.25 (t, J = 7.6 Hz, 2H), 6.86–6.96 (m, 3H, Ar-H), 7.25–7.32 (m, 5H, Ar-H ), 8.58 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 10.5 (CH3), 23.2 (CH2), 25.7 (CH2), 27.0 (CH2), 49.8 (CH2), 51.6 (CH2), 66.7 (CH2), 114.4 (CH), 120.9 (CH), 122.2 (CH), 122.3 (CH), 129.6 (CH), 135.2 (CH), 158.6 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −71.10 ; 31P NMR (CDCl3, 162 MHz): δ = −144.31 (sep, J = 712.8 Hz); IR (NaCl) υmax 3132 (C-H Ar), 1599–1471 (C=C), 1165(C-N), 1082 (C-O) cm−1; LCMS (M+)-PF6− 259.2 found for C16H23N2O+.
1-Propyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium trifluroacetate (15). 1H-NMR (CDCl3, 400 MHz): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.75 (quint, J = 7.6 Hz, 2H), 1.83 (sextet, J = 7.6 Hz, 2H), 2.03 (quint, J = 7.6 Hz, 2H), 3.92 (t, J = 7.6 Hz, 2H), 4.14 (t, J = 7.2 Hz, 2H), 4.33 (t, J = 7.6 Hz, 2H), 6.79–6.88 (m, 3H, Ar-H), 7.18–7.22 (m, 3H, Ar-H ), 7.40–7.47 (m, 2H, Ar-H ), 10.10 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 10.5 (CH3), 23.4 (CH2), 25.7 (CH2), 27.2 (CH2), 49.5 (CH2), 51.3 (CH2), 66.7 (CH2), 114.3 (CH), 120.8 (CH), 122.1 (CH), 122.2 (CH), 129.4 (CH), 137.0 (CH), 158.5 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −75.42; IR (NaCl) υmax 3131 (C-H Ar), 1599–1469 (C=C), 1166 (C-N), 1079 (C-O) cm−1; LCMS (M+)-CF3CO2− 259.2 found for C16H23N2O+.
1-Propyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium dicyanoamine (16). 1H-NMR (CDCl3, 400 MHz): δ = 0.91 (t, J = 7.2 Hz, 3H), 1.79 (quint, J = 7.6 Hz, 2H), 1.82 (sextet, J = 7.6 Hz, 2H), 2.08 (quint, J = 7.6 Hz, 2H), 3.95 (t, J = 7.6 Hz, 2H), 4.19 (t, J = 7.2 Hz, 2H), 4.36 (t, J = 7.6 Hz, 2H), 6.81–6.88 (m, 3H, Ar-H), 7.18–7.22 (m, 3H, Ar-H ), 7.45–7.51 (m, 2H, Ar-H ), 9.28 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 8.8 (CH3), 21.6 (CH2), 24.0 (CH2), 25.4 (CH2), 48.1 (CH2), 49.8 (CH2), 64.9 (CH2), 112.6 (CH), 118.9 (CH), 120.6 (CH), 120.7 (CH), 127.6 (CH), 134.0 (CH), 156.6 (C); IR (NaCl) υmax 3133 (C-H Ar), 1598–1472 (C=C), 1163 (C-N), 1080 (C-O) cm−1; LCMS (M+)-(CN)2N− 259.2 found for C16H23N2O+.
1-Propyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium thiocyanate (17). 1H-NMR (CDCl3, 400 MHz): δ = 0.89 (t, J = 7.2 Hz, 3H), 1.78 (quint, J = 7.6 Hz, 2H), 1.86 (sextet, J = 7.6 Hz, 2H), 2.03 (quint, J = 7.6 Hz, 2H), 3.93 (t, J = 7.6 Hz, 2H), 4.12 (t, J = 7.2 Hz, 2H), 4.29 (t, J = 7.6 Hz, 2H), 6.79–6.87 (m, 3H, Ar-H), 7.16–7.22 (m, 3H, Ar-H ), 7.39–7.46 (m, 2H, Ar-H ), 9.50 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 8.8 (CH3), 21.6 (CH2), 23.9 (CH2), 25.3 (CH2), 47.9 (CH2), 49.6 (CH2), 64.8 (CH2), 112.5 (CH), 119.0 (CH), 120.5 (CH), 120.6 (CH), 127.6 (CH), 134.1 (CH), 156.6 (C); IR (NaCl) υmax 3129 (C-H Ar), 1597–1469 (C=C), 1163 (C-N), 1079 (C-O) cm−1; LCMS (M+)-SCN− 259.2 found for C16H23N2O+.
1-Propyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium nitrate (18). 1H-NMR (CDCl3, 400 MHz): δ = 0.75 (t, J = 7.2 Hz, 3H), 1.63 (quint, J = 7.6 Hz, 2H), 1.74 (sextet, J = 7.6 Hz, 2H), 1.94 (quint, J = 7.6 Hz, 2H), 3.79 (t, J = 7.6 Hz, 2H), 4.07 (t, J = 7.2 Hz, 2H), 4.23 (t, J = 7.6 Hz, 2H), 6.66–6.74 (m, 3H, Ar-H), 7.03–7.07 (m, 3H, Ar-H ), 7.42–7.50 (m, 2H, Ar-H ), 9.92 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 10.6 (CH3), 23.4 (CH2), 25.7 (CH2), 27.1 (CH2), 49.4 (CH2), 51.2 (CH2), 66.6 (CH2), 114.3 (CH), 120.7 (CH), 122.3 (CH), 122.4 (CH), 129.3 (CH), 136.4 (CH), 156.4 (C); IR (NaCl) υmax 3132 (C-H Ar), 1598–1470 (C=C), 1165 (C-N), 1081 (C-O) cm−1; LCMS (M+)-NO3− 259.2 found for C16H23N2O+.
1-Butyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium tetrafluoroborate (19). 1H-NMR (CDCl3, 400 MHz): δ = 0.90 (t, J = 7.2 Hz, 3H), 1.33 (sextet, J = 7.6 Hz, 2H), 1.80–1.84 (m, J = 7.6 Hz, 4H), 2.12 (quint, J = 7.6 Hz, 2H), 3.96 (t, J = 7.6 Hz, 2H), 4.27 (t, J = 7.2 Hz, 2H), 4.43 (t, J = 7.6 Hz, 2H), 6.81–6.89 (m, 3H, Ar-H), 7.19–7.24 (m, 2H, Ar-H), 7.50–7.61 (m, 2H, Ar-H), 9.58 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 12.4 (CH3), 18.4 (CH2), 24.8 (CH2), 26.3 (CH2), 31.1 (CH2), 47.6 (CH2), 48.7 (CH2), 65.8 (CH2), 113.4 (CH), 119.8 (CH), 121.2 (CH), 121.4 (CH), 128.5 (CH), 135.6 (CH), 157.5 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −150.35; 11B-NMR (CDCl3, 128 MHz): δ = −0.98; IR (NaCl) υmax 3130 (C-H Ar), 1599–1471 (C=C), 1164 (C-N), 1082 (C-O) cm−1; LCMS (M+)-BF4− 273.3 found for C17H25N2O+.
1-Butyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium hexafluorophospate (20). 1H-NMR (CDCl3, 400 MHz): δ = 0.87 (t, J = 7.2 Hz, 3H), 1.30 (sextet, J = 7.6 Hz, 2H), 1.77–1.81 (m, J = 7.6 Hz, 4H), 2.09 (quint, J = 7.6 Hz, 2H), 3.92 (t, J = 7.6 Hz, 2H), 4.23 (t, J = 7.2 Hz, 2H), 4.39 (t, J = 7.6 Hz, 2H), 6.77–6.86 (m, 3H, Ar-H), 7.15–7.20 (m, 2H, Ar-H), 7.46–7.57 (m, 2H, Ar-H), 8.78 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 12.8 (CH3), 18.8 (CH2), 25.2 (CH2), 26.8 (CH2), 31.5 (CH2), 48.0 (CH2), 49.1 (CH2), 66.2 (CH2), 113.7 (CH), 120.2 (CH), 121.6 (CH), 121.6 (CH), 128.9 (CH), 136.0 (CH), 158.2 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −72.96; 31P NMR (CDCl3, 162 MHz): δ = −144.96 (sep, J = 712.8 Hz); IR (NaCl) υmax 3134 (C-H Ar), 1598–1469 (C=C), 1163 (C-N), 1080 (C-O) cm−1; LCMS (M+)-PF6− 273.3 found for C17H25N2O+.
1-Butyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium trifluroacetate (21). 1H-NMR (CDCl3, 400 MHz): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.32 (sextet, J = 7.6 Hz, 2H), 1.78-1.83 (m, J = 7.6 Hz, 4H), 2.10 (quint, J = 7.6 Hz, 2H), 3.94 (t, J = 7.6 Hz, 2H), 4.24 (t, J = 7.2 Hz, 2H), 4.41 (t, J = 7.6 Hz, 2H), 6.78–6.88 (m, 3H, Ar-H), 7.16–7.22 (m, 2H, Ar-H), 7.47–7.59 (m, 2H, Ar-H), 8.99 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.1 (CH3), 19.1 (CH2), 25.5 (CH2), 27.1 (CH2), 31.8 (CH2), 48.3 (CH2), 49.4 (CH2), 66.5 (CH2), 114.0 (CH), 120.6 (CH), 121.9 (CH), 121.9 (CH), 129.2 (CH), 136.3 (CH), 158.5 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −75.72;IR (NaCl) υmax 3132 (C-H Ar), 1599–1471 (C=C), 1165(C-N), 1082 (C-O) cm−1; LCMS (M+)-CF3CO2− 273.3 found for C17H25N2O+.
1-Butyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium dicyanoamine (22). 1H-NMR (CDCl3, 400 MHz): δ = 0.88 (t, J = 7.2 Hz, 3H), 1.31 (sextet, J = 7.6 Hz, 2H), 1.78–1.82 (m, J = 7.6 Hz, 4H), 2.10 (quint, J = 7.6 Hz, 2H), 3.94 (t, J = 7.6 Hz, 2H), 4.25 (t, J = 7.2 Hz, 2H), 4.41 (t, J = 7.6 Hz, 2H), 6.79–6.86 (m, 3H, Ar-H), 7.17–7.21 (m, 2H, Ar-H), 7.47–7.58 (m, 2H, Ar-H), 10.22 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.4 (CH3), 19.4 (CH2), 25.8 (CH2), 27.3 (CH2), 32.1 (CH2), 48.7 (CH2), 49.6 (CH2), 66.9 (CH2), 114.5 (CH), 120.8 (CH), 122.2 (CH), 122.4 (CH), 129.5 (CH), 136.6 (CH), 158.5 (C); IR (NaCl) υmax 3130 (C-H Ar), 1600–1470 (C=C), 1164 (C-N), 1081 (C-O) cm−1; LCMS (M+)-(CN)2N − 273.3 found for C17H25N2O+.
1-Butyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium thiocyanate (23). 1H-NMR (CDCl3, 400 MHz): δ = 0.92 (t, J = 7.2 Hz, 3H), 1.35 (sextet, J = 7.6 Hz, 2H), 1.82–1.86 (m, J = 7.6 Hz, 4H), 2.13 (quint, J = 7.6 Hz, 2H), 3.97 (t, J = 7.6 Hz, 2H), 4.28 (t, J = 7.2 Hz, 2H), 4.45 (t, J = 7.6 Hz, 2H), 6.79–6.86 (m, 3H, Ar-H), 7.17–7.21 (m, 2H, Ar-H), 7.47–7.58 (m, 2H, Ar-H), 8.99 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.4 (CH3), 19.4 (CH2), 25.8 (CH2), 27.3 (CH2), 32.1 (CH2), 48.7 (CH2), 49.6 (CH2), 66.8 (CH2), 114.4 (CH), 120.8 (CH), 122.2 (CH), 122.4 (CH), 129.5 (CH), 136.6 (CH), 158.5 (C); IR (NaCl) υmax 3128 (C-H Ar), 1599–1471 (C=C), 1162 (C-N), 1079 (C-O) cm−1; LCMS (M+)-SCN− 273.3 found for C17H25N2O+.
1-Butyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium nitrate (24). 1H-NMR (CDCl3, 400 MHz): δ = 0.90 (t, J = 7.2 Hz, 3H), 1.33 (sextet, J = 7.6 Hz, 2H), 1.80–1.84 (m, J = 7.6 Hz, 4H), 2.12 (quint, J = 7.6 Hz, 2H), 3.96 (t, J = 7.6 Hz, 2H), 4.27 (t, J = 7.2 Hz, 2H), 4.43 (t, J = 7.6 Hz, 2H), 6.81–6.89 (m, 3H, Ar-H), 7.19–7.24 (m, 2H, Ar-H), 7.50–7.61 (m, 2H, Ar-H), 8.89 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.0 (CH3), 19.1 (CH2), 25.4 (CH2), 27.1 (CH2), 31.7 (CH2), 48.3 (CH2), 49.3 (CH2), 66.5 (CH2), 113.9 (CH), 120.6 (CH), 121.8 (CH), 121.9 (CH), 129.1 (CH), 136.2 (CH), 158.5 (C); IR (NaCl) υmax 3131 (C-H Ar), 1598–1471 (C=C), 1163 (C-N), 1083 (C-O) cm−1; LCMS (M+)-NO3− 273.3 found for C17H25N2O+.
1-Pentyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium tetrafluoroborate (25). 1H-NMR (CDCl3, 400 MHz): δ = 0.87 (t, J = 7.2 Hz, 3H), 1.30–1.32 (m, 4H), 1.80–1.83 (m, 4H), 2.08 (quint, J = 7.6 Hz, 2H), 3.97 (t, J = 7.6 Hz, 2H), 4.15 (t, J = 7.2 Hz, 2H), 4.28 (t, J = 7.6 Hz, 2H), 6.85–6.92 (m, 3H, Ar-H), 7.23–7.27 (m, 2H, Ar-H), 7.35–7.42 (m, 2H, Ar-H), 8.90 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 11.9 (CH3), 20.1 (CH2), 23.9 (CH2), 25.3 (CH2), 26.3 (CH2), 27.8 (CH2), 47.9 (CH2), 48.2 (CH2), 64.9 (CH2), 112.6 (CH), 119.0 (CH), 120.5 (CH), 120.6 (CH), 127.7 (CH), 133.8 (CH), 156.8 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −151.03; 11B-NMR (CDCl3, 128 MHz): δ = −0.93; IR (NaCl) υmax 3135 (C-H Ar), 1601–1475 (C=C), 1165 (C-N), 1081 (C-O) cm−1; LCMS (M+)-BF4− 287.3 found for C18H27N2O+.
1-Pentyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium hexafluorophospate (26). 1H-NMR (CDCl3, 400 MHz): δ = 0.78 (t, J = 7.2 Hz, 3H), 1.21–1.23 (m, 4H), 1.67–1.75 (m, 4H), 1.95 (quint, J = 7.6 Hz, 2H), 3.86 (t, J = 7.6 Hz, 2H), 4.02 (t, J = 7.2 Hz, 2H), 4.13 (t, J = 7.6 Hz, 2H), 6.76–6.85 (m, 3H, Ar-H), 7.14–7.25 (m, 4H, Ar-H), 8.42 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 12.0 (CH3), 20.2 (CH2), 24.0 (CH2), 25.2 (CH2), 26.4 (CH2), 27.8 (CH2), 48.0 (CH2), 48.3 (CH2), 65.0 (CH2), 112.7 (CH), 119.1 (CH), 120.6 (CH), 120.7 (CH), 127.8 (CH), 133.2 (CH), 156.9 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −70.94 ; 31P NMR (CDCl3, 162 MHz): δ = −144.26 (sep, J = 712.8 Hz); IR (NaCl) υmax 3132 (C-H Ar), 1599–1469 (C=C), 1167 (C-N), 1084 (C-O) cm−1; LCMS (M+)-PF6− 287.3 found for C18H27N2O+.
1-Pentyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium trifluroacetate (27). 1H-NMR (CDCl3, 400 MHz): δ = 0.82 (t, J = 7.2 Hz, 3H), 1.21–1.29 (m, 4H), 1.74–1.82 (m, 4H), 2.05 (quint, J = 7.6 Hz, 2H), 3.93 (t, J = 7.6 Hz, 2H), 4.18 (t, J = 7.2 Hz, 2H), 4.34 (t, J = 7.6 Hz, 2H), 6.80–6.89 (m, 3H, Ar-H), 7.18–7.22 (m, 2H, Ar-H), 7.38–7.48 (m, 2H, Ar-H), 10.02 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 11.9 (CH3), 20.1 (CH2), 23.9 (CH2), 25.4 (CH2), 26.3 (CH2), 28.0 (CH2), 47.7 (CH2), 48.1 (CH2), 64.9 (CH2), 112.5 (CH), 119.0 (CH), 120.2 (CH), 120.5 (CH), 127.6 (CH), 135.1 (CH), 156.7 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −75.36 ; IR (NaCl) υmax 3135 (C-H Ar), 1599–1473 (C=C), 1165 (C-N), 1082 (C-O) cm−1; LCMS (M+)-CF3CO2− 287.3 found for C18H27N2O+.
1-Pentyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium dicyanoamine (28). 1H-NMR (CDCl3, 400 MHz): δ = 0.82 (t, J = 7.2 Hz, 3H), 1.21–1.30 (m, 4H), 1.75–1.84 (m, 4H), 2.06 (quint, J = 7.6 Hz, 2H), 3.94 (t, J = 7.6 Hz, 2H), 4.15 (t, J = 7.2 Hz, 2H), 4.30 (t, J = 7.6 Hz, 2H), 6.79–6.87 (m, 3H, Ar-H), 7.17–7.21 (m, 2H, Ar-H), 7.38–7.47 (m, 2H, Ar-H), 9.56 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 11.9 (CH3), 20.0 (CH2), 23.9 (CH2), 25.4 (CH2), 26.3 (CH2), 27.8 (CH2), 47.9 (CH2), 48.2 (CH2), 64.8 (CH2), 112.5 (CH), 119.0 (CH), 120.5 (CH), 120.6 (CH), 127.6 (CH), 134.1 (CH), 156.6 (C); IR (NaCl) υmax 3129 (C-H Ar), 1598–1471 (C=C), 1163 (C-N), 1079 (C-O) cm−1; LCMS (M+)-(CN)2N− 287.3 found for C18H27N2O+.
1-Pentyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium thiocyanate (29). 1H-NMR (CDCl3, 400 MHz): δ = 0.85 (t, J = 7.2 Hz, 3H), 1.24–1.33 (m, 4H), 1.78–1.87 (m, 4H), 2.09 (quint, J = 7.6 Hz, 2H), 3.97 (t, J = 7.6 Hz, 2H), 4.18 (t, J = 7.2 Hz, 2H), 4.33 (t, J = 7.6 Hz, 2H), 6.82–6.90 (m, 3H, Ar-H), 7.20–7.24 (m, 2H, Ar-H), 7.41–7.50 (m, 2H, Ar-H), 9.59 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 11.8 (CH3), 19.9 (CH2), 23.8 (CH2), 25.3 (CH2), 26.2 (CH2), 27.7 (CH2), 47.8 (CH2), 48.1 (CH2), 64.7 (CH2), 112.4 (CH), 118.9 (CH), 120.4 (CH), 120.5 (CH), 127.5 (CH), 134.0 (CH), 156.5 (C); IR (NaCl) υmax 3132 (C-H Ar), 1599–1471 (C=C), 1165 (C-N), 1085 (C-O) cm−1; LCMS (M+)-SCN− 287.3 found for C18H27N2O+.
1-Pentyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium nitrate (30). 1H-NMR (CDCl3, 400 MHz): δ = 0.76 (t, J = 7.2 Hz, 3H), 1.20–1.37 (m, 4H), 1.70–1.79 (m, 4H), 2.03 (quint, J = 7.6 Hz, 2H), 3.88 (t, J = 7.6 Hz, 2H), 4.17 (t, J = 7.2 Hz, 2H), 4.34 (t, J = 7.6 Hz, 2H), 6.74–6.83 (m, 3H, Ar-H), 7.12–7.16 (m, 2H, Ar-H), 7.44–7.57 (m, 2H, Ar-H), 10.07 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.7 (CH3), 21.9 (CH2), 25.8 (CH2), 27.2 (CH2), 28.1 (CH2), 29.8 (CH2), 49.5 (CH2), 49.9 (CH2), 66.7 (CH2), 114.3 (CH), 120.7 (CH), 122.2 (CH), 122.5 (CH), 129.4 (CH), 136.6 (CH), 158.5 (C); IR (NaCl) υmax 3130 (C-H Ar), 1599–1471 (C=C), 1163 (C-N), 1082 (C-O) cm−1; LCMS (M+)-NO3− 287.3 found for C18H27N2O+.
1-Hexyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium tetrafluoroborate (31). 1H-NMR (CDCl3, 400 MHz): δ = 0.98 (t, J = 7.2 Hz, 3H), 1.18 (quint, J = 7.6 Hz, 2H), 1.43–1.45 (m, 4H), 1.73 (quint, J = 7.6 Hz, 2H), 1.81 (quint, J = 7.6 Hz, 2H), 2.00 (quint, J = 7.6 Hz, 2H), 4.00 (t, J = 7.6 Hz, 2H), 4.31 (quint, J = 7.2 Hz, 2H), 4.50 (t, J = 7.6 Hz, 2H), 6.91–6.95 (m, 3H, Ar-H), 7.26–7.31 (m, 2H, Ar-H), 7.97–8.01 (m, 2H, Ar-H), 9.32 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 14.1 (CH3), 22.8 (CH2), 25.0 (CH2), 27.4 (CH2), 27.5 (CH2), 32.8 (CH2), 34.1 (CH2), 44.3 (CH2), 48.5 (CH2), 66.8 (CH2), 114.5 (CH), 120.4 (CH), 122.3 (CH), 122.5 (CH), 130.0 (CH), 136.2 (CH), 158.7 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −148.25; 11B-NMR (CDCl3, 128 MHz): δ = −1.26; IR (NaCl) υmax 3129 (C-H Ar), 1602–1474 (C=C), 1165 (C-N), 1082 (C-O) cm−1; LCMS (M+)-BF4− 301.3 found for C19H29N2O+.
1-Hexyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium hexafluorophospate (32). 1H-NMR (CDCl3, 400 MHz): δ = 0.85 (t, J = 7.2 Hz, 3H), 1.12 (quint, J = 7.6 Hz, 2H), 1.25–1.34 (m, 4H), 1.79–1.88 (m, 4H), 2.10 (quint, J = 7.6 Hz, 2H), 3.97 (t, J = 7.6 Hz, 2H), 4.18 (t, J = 7.2 Hz, 2H), 4.33 (t, J = 7.6 Hz, 2H), 6.83–6.91 (m, 3H, Ar-H), 7.21–7.25 (m, 2H, Ar-H), 7.42–7.51 (m, 2H, Ar-H), 9.24 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 11.9 (CH3), 20.0 (CH2), 23.9 (CH2), 25.4 (CH2), 26.4 (CH2), 27.8 (CH2), 32.2 (CH2), 45.9 (CH2), 48.2 (CH2), 64.8 (CH2), 112.5 (CH), 119.0 (CH), 120.5 (CH), 120.6 (CH), 127.6 (CH), 134.2 (CH), 156.7 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −71.10; 31P NMR (CDCl3, 162 MHz): δ = −144.16 (sep , J = 712.8 Hz); IR (NaCl) υmax 3133 (C-H Ar), 1599–1471 (C=C), 1165 (C-N), 1083 (C-O) cm−1; LCMS (M+)- PF6− 301.3 found for C19H29N2O+.
1-Hexyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium trifluroacetate (33). 1H-NMR (CDCl3, 400 MHz): δ = 0.79 (t, J = 7.2 Hz, 3H), 1.07 (quint, J = 7.6 Hz, 2H), 1.20–1.29 (m, 4H), 1.75–1.84 (m, 4H), 2.05 (quint, J = 7.6 Hz, 2H), 3.92 (t, J = 7.6 Hz, 2H), 4.13 (t, J = 7.2 Hz, 2H), 4.28 (t, J = 7.6 Hz, 2H), 6.79–6.87 (m, 3H, Ar-H), 7.17–7.23 (m, 2H, Ar-H), 7.38–7.47 (m, 2H, Ar-H), 10.15 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.0 (CH3), 21.1 (CH2), 24.0 (CH2), 26.5 (CH2), 27.6 (CH2), 28.9 (CH2), 33.4 (CH2), 47.0 (CH2), 49.3 (CH2), 65.9 (CH2), 113.6 (CH), 120.1 (CH), 121.6 (CH), 121.7 (CH), 128.7 (CH), 135.3 (CH), 157.8 (C); 19F-NMR (CDCl3, 376.5 MHz): δ = −75.41 ;IR (NaCl) υmax 3133 (C-H Ar), 1599–1472 (C=C), 1162 (C-N), 1080 (C-O) cm−1; LCMS (M+)-CF3CO2− 301.3 found for C19H29N2O+.
1-Hexyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium dicyanoamine (34). 1H-NMR (CDCl3, 400 MHz): δ = 0.76 (t, J = 7.2 Hz, 3H), 1.04 (quint, J = 7.6 Hz, 2H), 1.20–1.37 (m, 4H), 1.70–1.79 (m, 4H), 2.03 (quint, J = 7.6 Hz, 2H), 3.88 (t, J = 7.6 Hz, 2H), 4.17 (t, J = 7.2 Hz, 2H), 4.34 (t, J = 7.6 Hz, 2H), 6.74–6.83 (m, 3H, Ar-H), 7.12–7.16 (m, 2H, Ar-H), 7.44–7.57 (m, 2H, Ar-H), 10.07 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 13.7 (CH3), 21.9 (CH2), 25.8 (CH2), 27.2 (CH2), 28.1 (CH2), 29.8 (CH2), 35.4 (CH2), 49.5 (CH2), 49.9 (CH2), 66.7 (CH2), 114.3 (CH), 120.7 (CH), 122.2 (CH), 122.5 (CH), 129.4 (CH), 136.6 (CH), 158.5 (C);IR (NaCl) υmax 3133 (C-H Ar), 1599–1471 (C=C), 1165 (C-N), 1082 (C-O) cm−1; LCMS (M+)-(CN)2N− 301.3 found for C19H29N2O+.
1-Hexyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium thiocyanate (35). 1H-NMR (CDCl3, 400 MHz): δ = 0.82 (t, J = 7.2 Hz, 3H), 1.10 (quint, J = 7.6 Hz, 2H), 1.21–1.29 (m, 4H), 1.74–1.82 (m, 4H), 2.05 (quint, J = 7.6 Hz, 2H), 3.93 (t, J = 7.6 Hz, 2H), 4.18 (t, J = 7.2 Hz, 2H), 4.34 (t, J = 7.6 Hz, 2H), 6.80–6.89 (m, 3H, Ar-H), 7.18–7.22 (m, 2H, Ar-H), 7.38–7.48 (m, 2H, Ar-H), 10.02 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 11.9 (CH3), 20.1 (CH2), 23.9 (CH2), 25.4 (CH2), 26.3 (CH2), 28.0 (CH2), 34.0 (CH2), 47.7 (CH2), 48.1 (CH2), 64.9 (CH2), 112.5 (CH), 119.0 (CH), 120.2 (CH), 120.5 (CH), 127.6 (CH), 135.1 (CH), 156.7 (C); IR (NaCl) υmax 3128 (C-H Ar), 1602–1471 (C=C), 1164 (C-N), 1081 (C-O) cm−1; LCMS (M+)-SCN − 301.3 found for C19H29N2O+.
1-Hexyl-3-(4-phenoxybutyl)-1H-imidazol-3-ium nitrate (36). 1H-NMR (CDCl3, 400 MHz): δ = 0.85 (t, J = 7.2 Hz, 3H), 1.14 (quint, J = 7.6 Hz, 2H), 1.24–1.33 (m, 4H), 1.78–1.87 (m, 4H), 2.09 (quint, J = 7.6 Hz, 2H), 3.97 (t, J = 7.6 Hz, 2H), 4.18 (t, J = 7.2 Hz, 2H), 4.33 (t, J = 7.6 Hz, 2H), 6.82–6.90 (m, 3H, Ar-H), 7.20–7.24 (m, 2H, Ar-H), 7.41–7.50 (m, 2H, Ar-H), 9.59 (s, 1H, Ar-H); 13C-NMR (CDCl3, 100 MHz): δ = 11.8 (CH3), 19.9 (CH2), 23.8 (CH2), 25.3 (CH2), 26.2 (CH2), 27.7 (CH2), 34.2 (CH2), 47.8 (CH2), 48.1 (CH2), 64.7 (CH2), 112.4 (CH), 118.9 (CH), 120.4 (CH), 120.5 (CH), 127.5 (CH), 134.0 (CH), 156.5 (C);IR (NaCl) υmax 3131 (C-H Ar), 1598–1470 (C=C), 1164 (C-N), 1081 (C-O) cm−1; LCMS (M+)-NO3− 301.3 found for C19H29N2O+.

3.4. Determination of Minimum Inhibitory Concentrations

Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method based on recommended protocolemployed by the Clinical and Laboratory Standards Institute [41]. Tested compounds were dissolved in sterile, distilled water and diluted to a final concentration of 512 µg/mL in Mueller-Hinton broth (Becton Dickinson, Franklin Lakes, NJ, USA) [42]. Two-fold serially diluted test compounds were dispensed into each of the 96 wells of a standard microdilution plates. The direct colony suspension method was used for inoculum preparation. Bacterial suspension was prepared by direct transfer of colonies from 24 h agar plates to Mueller Hinton broth. Bacterial suspensions were adjusted using bacterial counting chamber to contain approximately 1 × 108 CFU/mL. A 50 µL volume of each bacterial suspension was mixed with 50 µL serially diluted tested compound in 96 microdilution plate according to the microdilution method [43]. Uninoculated wells were prepared as control samples.Plates were incubated at 35 °C for 24 h. The minimum (inhibitory) bactericidal concentration was defined as the lowestconcentration of test compound producing no visible growth. Confirmation for MIC, was achieved by transfer of aliquots from wells containing no growth on to nutrient agar plates and tested for colony formation upon subculturing. Given values of obtained MIC values are means of three independent experiments.

4. Conclusions

In summary, new eco-friendly 1-alkyl-3-(4-phenoxybutyl) imidazolium-based ionic liquids (ILs) derivatives were prepared by using ultrasound irradiation. Many advantages for the ultrasound assisted synthesis compared with the standard methods have been recorded. The ILs studied displayed a very promising antimicrobial activity. Their activities are greatly affected by the alkyl chain length. The study of the physicochemical properties, water content, biodegradability and solubility of the newly synthesized ionic liquids will be will be discussed in details in the forthcoming paper.

Acknowledgments

We gratefully acknowledge the financial support from Taibah University through the deanship of the scientific research (Grant 6084). T. Ben Hadda would like to thank the ACTELION; the Biopharmaceutical Company of Swiss, for the molecular properties calculations.

Author Contributions

This work is part of a pharmacological field study carried out in Taibah University, Madinah, KSA. The Ionic liquids were prepared and characterised by Mouslim Messali, Mohamed R. Aouad, Adeeb Al-Sheikh Ali. The manuscript is written by Mouslim Messali. Taibi Ben Hadda and Belkheir Hammouti help in illustrations and drafting of manuscript. Mohamed R. Aouad, Wael S. El-Sayed, Adeeb Al-Sheikh Ali collected data in the field and help in compounds identification. The biological activity is carried out by Wael S. El-Sayed. Taibi Ben Hadda provided technical expertise in compiling POM data in to the manuscript. All the authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Welton, T. Room-temperature ionic liquids. Solvents for synthesis and catalysis. Chem. Rev. 1999, 99, 2071–2083. [Google Scholar] [CrossRef]
  2. Davis, J.H., Jr. Task-Specific Ionic Liquids. Chem. Lett. 2004, 33, 1072–1077. [Google Scholar] [CrossRef]
  3. Cho, C.W.; Pham, T.P.; Jeon, Y.C.; Vijayaraghavan, K.; Choe, W.S.; Yun, Y.S. Toxicity of imidazolium salt with anion bromide to a phytoplankton Selenastrum capricornutum: Effect of alkyl-chain length. Chemosphere 2007, 69, 1003–1007. [Google Scholar] [CrossRef]
  4. Ventura, S.P.; Goncalves, A.M.M.; Goncalves, F.; Coutinho, J.A. Assessing the toxicity on [C3mim][Tf2N] to aquatic organisms of different trophic levels. Aquat. Toxicol. 2010, 96, 290–297. [Google Scholar] [CrossRef]
  5. Docherty, K.M.; Kulpa, C.F. Toxicity and antimicrobial activity of imidazo- lium and pyridinium ionic liquids. Green Chem. 2005, 7, 185–189. [Google Scholar] [CrossRef]
  6. Endres, F. Ionic liquids: Solvents for the electrodeposition of metals and semiconductors. Chem. Phys. Chem. 2002, 3, 144–154. [Google Scholar]
  7. Ibrahim, M.A.M.; Messali, M. Ionic Liquid [BMPy] Br as an effective additive auring Zinc electrodeposition from an aqueous Sulfate bath. Prod. Finish. 2011, 2, 14. [Google Scholar]
  8. Lin, Y.F.; Sun, I.W. Electrodeposition of zinc from a Lewis acidic zinc chloride-1-ethyl-3-methylimidazolium chloride molten salt. Electrochim. Acta 1999, 44, 2771–2777. [Google Scholar] [CrossRef]
  9. Da Costa Lopes, A.M.; João, K.G.; Morais, A.R.C.; Bogel-Łukasik, E.; Bogel-Łukasik, R. Ionic liquids as a tool for lignocellulosic biomass fractionation. Sustain. Chem. Process 2013, 1, 3. [Google Scholar]
  10. Liu, J.; Jiang, G.; Chi, Y.; Cai, Y.; Zhou, Q.; Hu, J. Use of ionic liquids for liquid-phase microextraction of polycyclic aromatic hydrocarbons. Anal. Chem. 2003, 21, 5870–5876. [Google Scholar]
  11. Zhang, Q.H.; Zhang, S.G.; Deng, Y.Q. Recent advances in ionic liquid catalysis. Green Chem. 2011, 13, 2619–2637. [Google Scholar] [CrossRef]
  12. Wang, J.H.; Cheng, D.H.; Chen, X.Y.; Du, Z.; Fang, Z.L. Direct extraction of double stranded DNA into ionic liquid 1-butyl-3-methylimidazolium hexafluorophosphate and its quantification. Anal. Chem. 2007, 79, 620–625. [Google Scholar]
  13. Moniruzzaman, M.; Kamiya, N.; Goto, M. Activation and stabilization of enzymes in ionic liquids. Org. Biomol. Chem. 2010, 8, 2887–2899. [Google Scholar] [CrossRef]
  14. Moniruzzaman, M.; Nakashima, K.; Kamiya, N.; Goto, M. Recent advances of enzymatic reactions in ionic liquids. Biochem. Eng. J. 2010, 48, 295–314. [Google Scholar]
  15. Muginova, S.V.; Galimova, A.Z.; Polyakov, A.E.; Shekhovtsova, T.N. Ionic liquids in enzymatic catalysis and biochemical methods of analysis: Capabilities and prospects. J. Anal. Chem. 2010, 65, 331–351. [Google Scholar]
  16. Pinto, P.C.A.G.; Saraiva, M.L.M.F.S.; Lima, J.L.F.C. Sequential injection analysis as a tool for implementation of enzymatic assays in ionic liquids. Talanta 2008, 77, 479–483. [Google Scholar] [CrossRef]
  17. Ibrahim, M.A.M.; Messali, M.; Moussa, Z.; Alzahrani, A.Y.; Alamry, S.N.; Hammouti, B. Corrosion inhibition of carbon steel by imidazolium and pyridiniumcations ionic liquids in acidic environment. Port. Electrochim. Acta 2011, 29, 375–389. [Google Scholar] [CrossRef]
  18. Messali, M. A green microwave-assisted synthesis, characterization and comparative study of new pyridazinium-based ionic liquids derivatives towards corrosion of mild steel in acidic environment. J. Mater. Environ. Sci. 2011, 2, 174–185. [Google Scholar]
  19. Zarrouk, A.; Messali, M.; Zarrok, H.; Salghi, R.; Al-Sheikh Ali, A.; Hammouti, B.; Al-Deyab, S.S.; Bentiss, F. Synthesis, characterization and comparative study of new functionalized imidazolium-based ionic liquids derivatives towards corrosion of C38 steel in molar hydrochloric acid. Int. J. Electrochem. Sci. 2012, 7, 6998–7015. [Google Scholar]
  20. Zarrouk, A.; Messali, M.; Aouad, M.R.; Zarrok, H.; Salghi, R.; Hammouti, B.; Chetouani, A. Some new ionic liquids derivatives: Synthesis, characterization and comparative study towards corrosion of C-steel in acidic media. J. Chem. Pharm. Res. 2012, 4, 3427–3436. [Google Scholar]
  21. Biswas, A.; Shogren, R.L.; Stevenson, D.G.; Willett, J.L.; Bhowmik, P.K. Ionic liquids as solvents for biopolymers: Acylation of starch and zein protein. Carbohydr. Polym. 2006, 66, 546–550. [Google Scholar] [CrossRef]
  22. Rao, C.J.; Venkatesan, K.A.; Nagarajan, K.; Srinivasan, T.G.; Rao, P.R.V. Treatment of tissue paper containing radioactive waste and electrochemical recovery of valuables using ionic liquids. Electrochim. Acta 2007, 53, 1911–1919. [Google Scholar] [CrossRef]
  23. Anastas, P.T.; Warner, J.C. Green Chemistry, Theory and Practice; Oxford University Press: Oxford, UK, 1998. [Google Scholar]
  24. Deetlefs, M.; Seddon, K.R. Improved preparations of ionic liquids using microwave irradiation. Green Chem. 2003, 5, 181–186. [Google Scholar]
  25. Singh, V.; Kaur, S.; Sapehiyia, V.; Singh, J.; Kad, G.L. Microwave accelerated preparation of [bmim][HSO4] ionic liquid: An acid catalyst for improved synthesis of coumarins. Catal. Commun. 2005, 6, 57–60. [Google Scholar] [CrossRef]
  26. Aupoix, A.; Pegot, B.; Vo-Thanh, G. Synthesis of imidazolium and pyridinium-based ionic liquids and application of 1-alkyl-3-methylimidazolium salts as pre-catalysts for the benzoin condensation using solvent-free and microwave activation. Tetrahedron 2010, 66, 1352–1356. [Google Scholar] [CrossRef]
  27. Messali, M.; Ahmed, S.A. A green microwave-assisted synthesis of new pyridazinium-based ionic liquids as an environmentally friendly alternative. Green Sustain. Chem. 2011, 1, 70–75. [Google Scholar]
  28. Pernak, J.; Sobaszkiewicz, K.; Mirska, I. Anti-microbial activities of ionic liquids. Green Chem. 2003, 5, 52–56. [Google Scholar] [CrossRef]
  29. Pernak, J.; Goc, I.; Mirska, I. Anti-microbial activities of protic ionic liquids with lactate anion. Green Chem. 2004, 6, 323–329. [Google Scholar]
  30. Pernak, J.; Feder-Kubis, J. Synthesis and properties of chiral ammonium- based ionic liquids. Chem. Eur. J. 2005, 11, 4441–4449. [Google Scholar] [CrossRef]
  31. Demberelnyamba, D.; Lim, K.S.; Choi, S.; Park, S.Y.; Lee, H.; Kim, C.J.; Yoo, I.D. Synthesis and antimicrobial properties of imidazolium and pyrrolidinonium salts. Bioorg. Med. Chem. 2004, 12, 853–857. [Google Scholar]
  32. Carson, L.; Chau, P.K.W.; Earle, M.J.; Gilea, M.A.; Gilmore, B.F.; Gorman, S.P.; McCann, M.T.; Seddon, K.R. Antibiofilm activities of 1-alkyl-3-methylimidazolium chloride ionic liquids. Green Chem. 2009, 11, 492–497. [Google Scholar]
  33. Messali, M.; Moussa, Z.; Alzahrani, A.Y.; El-Naggar, M.Y.; ElDouhaibi, A.S.; Judeh, Z.M.A.; Hammouti, B. Synthesis, characterization, antimicrobial activity of new green-chemistry-friendly ionic liquids. Chemosphere 2013, 91, 1627. [Google Scholar]
  34. Messali, M. An efficient and green sonochemical synthesis of some new eco-friendly functionalized ionic liquids. Arab. J. Chem. 2014, 7, 63–70. [Google Scholar] [CrossRef]
  35. Messali, M.; Asiri, M.A.M. A green ultrasound-assisted access to some new 1-benzyl-3-(4-phenoxybutyl) imidazolium-based ionic liquids derivatives—Potential corrosion inhibitors of mild steel in acidic environment. J. Mater. Environ. Sci. 2013, 5, 770–785. [Google Scholar]
  36. Al-Ghamdi, A.F.; Messali, M.; Ahmed, S.A. Electrochemical studies of new pyridazinium-based ionic liquid and its determination in different detergents. J. Mater. Environ. Sci. 2011, 3, 215–224. [Google Scholar]
  37. Messali, M. A facile and green microwave-assisted synthesis of new functionalized picolinium-based ionic liquids. Arab. J. Chem. 2011. [Google Scholar] [CrossRef]
  38. Bonhote, P.; Dias, A.P.; Papageorgiou, N.; Kalyanasundaram, K.; Graetzel, M. Hydrophobic, highly conductive ambient-temperaturemolten salts. Inorg. Chem. 1996, 35, 1168–1178. [Google Scholar]
  39. Poole, C.F. Chromatographic and spectroscopic methods for thedetermination of solvent properties of room-temperature ionic liquids. J. Chromatogr. A 2004, 1037, 49–82. [Google Scholar] [CrossRef]
  40. Hossain, M.I.; El-Harbawi, M.; Noaman, Y.A.; Bustam, M.A.B.; Alitheen, N.B.M.; Affandi, N.A.; Hefter, G.; Yin, C.Y. Synthesis and anti-microbial activity of hydroxylammonium ionic liquids. Chemosphere 2011, 84, 101–104. [Google Scholar] [CrossRef]
  41. Jorgensen, J.H. M26-A: Methods of Determining Bactericidal Activity of Antimicrobial Agents for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved guideline; Clinical and Laboratory Standards Institute (CLSI): Wayne, PA, USA, 1999. [Google Scholar]
  42. Nomura, H.; Isshiki, Y.; Sakuda, K.; Sakuma, K.; Kondo, S. The antibacterial activity of compounds isolated from oakmoss against Legionella pneumophila and Other Legionella spp. Biol. Pharm. Bull. 2012, 35, 1560–1567. [Google Scholar]
  43. M7-A5: Methods for Antibacterial Susceptibility Test for Bacteria that Grow Aerobically, Approved Standard, 5th ed.; Clinical and Laboratory Standards Institute (CLSI): Wayne, PA, USA, 2000.
  • Sample Availability: Not available.

Share and Cite

MDPI and ACS Style

Messali, M.; Aouad, M.R.; El-Sayed, W.S.; Al-Sheikh Ali, A.; Ben Hadda, T.; Hammouti, B. New Eco-Friendly 1-Alkyl-3-(4-phenoxybutyl) Imidazolium-Based Ionic Liquids Derivatives: A Green Ultrasound-Assisted Synthesis, Characterization, Antibacterial Activity and POM Analyses. Molecules 2014, 19, 11741-11759. https://doi.org/10.3390/molecules190811741

AMA Style

Messali M, Aouad MR, El-Sayed WS, Al-Sheikh Ali A, Ben Hadda T, Hammouti B. New Eco-Friendly 1-Alkyl-3-(4-phenoxybutyl) Imidazolium-Based Ionic Liquids Derivatives: A Green Ultrasound-Assisted Synthesis, Characterization, Antibacterial Activity and POM Analyses. Molecules. 2014; 19(8):11741-11759. https://doi.org/10.3390/molecules190811741

Chicago/Turabian Style

Messali, Mouslim, Mohamed R. Aouad, Wael S. El-Sayed, Adeeb Al-Sheikh Ali, Taibi Ben Hadda, and Belkheir Hammouti. 2014. "New Eco-Friendly 1-Alkyl-3-(4-phenoxybutyl) Imidazolium-Based Ionic Liquids Derivatives: A Green Ultrasound-Assisted Synthesis, Characterization, Antibacterial Activity and POM Analyses" Molecules 19, no. 8: 11741-11759. https://doi.org/10.3390/molecules190811741

APA Style

Messali, M., Aouad, M. R., El-Sayed, W. S., Al-Sheikh Ali, A., Ben Hadda, T., & Hammouti, B. (2014). New Eco-Friendly 1-Alkyl-3-(4-phenoxybutyl) Imidazolium-Based Ionic Liquids Derivatives: A Green Ultrasound-Assisted Synthesis, Characterization, Antibacterial Activity and POM Analyses. Molecules, 19(8), 11741-11759. https://doi.org/10.3390/molecules190811741

Article Metrics

Back to TopTop